Pierre Fabre sign a new partnership with VibioSphen, within the framework of the Open Innovation program “Nature Open Library”
Pierre Fabre laboratories and VibioSphen, a young biotechnology company from the Toulouse region specializing in infectious disease, announced today the signature of a new partnership agreement within the framework of “Nature Open Library”, a new and different Open Innovation program launched last December by Pierre Fabre to share its private plants’ collection and its expertise of the whole phyto-industrial value chain with innovating companies from all sectors. Following a first partnership signed in February 2016 with the British biotechnology company Plasticell, this new collaboration is the second one that falls within the framework of this initiative.
VibioSphen will first screen Pierre Fabre‘s plants’ collection, one of the most important in the industry, numbering over 15.000 classified samples and phyto-chemical compounds. Via this targeted screening, VibioSphen will try to identify new natural molecules which could be tested afterwards on several models of infectious diseases. Under the terms of the agreement, if this screening phase is carried out successfully, Pierre Fabre Laboratories will then become VibioSphen’s preferred partners for the further development of identified molecules.
This second partnership confirms the interest rouse by our Nature Open Library initiative. We are especially glad to implement it with a biotech company from the Toulouse region which makes its dynamism available for the further development of therapies in the field of infectious diseases, a medical field with the utmost importance not included in our R&D program but which could benefit from the given opportunities via our plants’ collection, stated Laurent Audoly, Pierre Fabre Pharmaceuticals R&D Director commenting this new agreement.
This partnership is a real opportunity for us to develop our portfolio of molecules. Through this collaboration, VibioSphen will benefit from the expertise of a major group like Pierre Fabre. The access to these natural extracts and to pre-qualified molecules will help us identify more quickly drug candidates. New therapies can be discovered via natural molecules to fight against antibiotic resistant bacteria, commented Maxime Fontanié, VibioSphen’s CEO.